Validation of the OncoMasTR Risk Score in Estrogen Receptor-Positive/HER2-Negative Patients: a TransATAC study.

CONCLUSIONS: OMm, OMclin1 and OMclin2 were highly prognostic for early and late DR in women with early-stage ER-positive breast cancer receiving 5 years' endocrine therapy. In TransATAC OMclin1 and the OncoMasTR Risk Score (OMclin2) were superior to RS in identifying patients at increased risk of DR.
PMID: 31641007 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - October 21, 2019 Category: Cancer & Oncology Authors: Buus R, Sestak I, Barron S, Loughman T, Fender B, Ruiz CL, Dynoodt P, Wang CA, O'Leary D, Gallagher WM, Dowsett M, Cuzick J Tags: Clin Cancer Res Source Type: research